ReviewWorld journal of microbiology & biotechnology2025
Recent progress in the microbial production of Xylanase.
Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enzymatic production of prebiotic xylooligosaccharides.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Endo-1,4-β-D-xylanase (EC 3.2.1.8, abbreviated as xylanase) is widely distributed in various plant-associated mollusks, insects, and microorganisms, catalyzing the degradation of xylan-a major component of plant cell walls. Based on their diverse catalytic mechanisms toward xylan chains, major xylanases from microbial species are summarized and categorized into various glycoside hydrolase (GH) families through phylogenetic analysis in this review. Xylanases, particularly GH10 and GH11 families, play versatile and critical roles in many plant-based industries, including food and feed, biofuels, pulp and paper, and pharmaceuticals. Nevertheless, persistent challenges of xylanases during practical applications are pointed out as their properties and microbial production occurs because native xylanases show weak operational stability under extreme conditions (high temperature, pH extremes, high salinity). To improve the performance of xylanases, protein engineering technique for xylanase structure optimization, and amino acid modification is analyzed as a powerful approach in many cases. In parallel, famous industrial microbial chassis, such as Escherichia coli, Komagataella phaffii systems for recombinant xylanase production are proved as a solution of growing industrial demand of xylanases recently. The strategy of combining emerging technologies with "design-production-immobilization-application" technological cycle is proposed as the key development direction of xylanase based on the systematic evaluation of the status, challenges, and development prospects of microbial xylanases production, encompassing xylanase characteristics, structure modification and production, applications and future directions.
Indexed as
Identifiers
41273491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.